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Objectives. Admission hyperglycemia and B-type natriuretic peptide (BNP) are associated with mortality in acute coronary
syndromes, but no study compares their prediction in-hospital death. Methods. Patients with non-ST-elevation myocardial
infarction (NSTEMI), in-hospital mortality and two-year mortality or readmission were compared for area under the curve
(AUC), sensitivity (SEN), specificity (SPE), positive predictive value (PPV), negative predictive value (NPV), and accuracy (ACC)
of glycemia and BNP. Results. Respectively, AUC, SEN, SPE, PPV, NPV, and ACC for prediction of in-hospital mortality were 0.815,
71.4%, 84.3%, 26.3%, 97.4%, and 83.3% for glycemia = 200mg/dL and 0.748, 71.4%, 68.5%, 15.2%, 96.8% and 68.7% for BNP =
300 pg/mL. AUC of glycemia was similar to BNP (P = 0.411). In multivariate analysis we found glycemia ≥200mg/dL related to
in-hospital death (P = 0.004). No diﬀerence was found in two-year mortality or readmission in BNP or hyperglycemic subgroups.
Conclusion. Hyperglycemia was an independent risk factor for in-hospital mortality in NSTEMI and had a good ROC curve level.
Hyperglycemia and BNP, although poor in-hospital predictors of unfavorable events, were independent risk factors for death or
length of stay >10 days. No relation was found between hyperglycemia or BNP and long-term events.
1. Introduction
In recent years, incorporation of new laboratory methods
in clinical practice has improved diagnosis and prognostic
prediction of outcomes in acute coronary syndromes (ACS).
Cardiac troponins, with high sensitivity and specificity for
diagnosing myocardial injury [1], and B type natriuretic
factor (BNP), primarily used in acute decompensation of
heart failure but with prognostic significance in ACS [2], are
useful in the initial evaluation of patients with acute chest
pain [3–5]. Glycemia, determined by using a simple, low-cost
laboratory test, has been associated with a worse prognosis in
ACS patients, even in the absence of diabetes [6].
Studies have shown BNP as a prognostic factor for both
early and late outcomes in non-ST elevation ACS, a pre-
sumed reflection of left ventricular dysfunction [7]. Non-
ST elevation myocardial infarction (NSTEMI) has lower in-
hospital mortality than ST elevation myocardial infarction
has, but higher unadjusted events in years following hospi-
talization [8]. So, we hypothesized that hyperglycemia and
BNP could predict patients at risk for both in-hospital and
2-year events.
2. Methods
2.1. Study Design and Population. Patients with ACS admit-
ted consecutively between January 2005 and April 2006 to
an urban academic cardiology emergency single center in
Sa˜o Paulo, Brazil were prospectively evaluated with their
data registered in the institution’s database. Baseline clinical
and admission laboratory characteristics, CAD risk factors,
medicines used, in-hospital outcomes, angiography, and
treatments were observed. The Ethics Committee of the
hospital approved this study. A total of 1304 ACS patients
were included, and a subgroup of 170 NSTEMI-only patients
with admission BNP were followed up for two years.
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Inclusion criteria were ACS hospital admission, according
to the international consensus definition [9], age older
than 18 years, and willing to provide written informed
consent. Exclusion criteria were non-NSTEMI ACS and
incomplete laboratory data. Completed data were available
for 96 NSTEMI patients, and written informed consent was
obtained from all participants.
2.2. Definitions and Data Collection. Clinical outcomes were
defined as death, or death and prolonged length of stay (>10
days; mean of length of stay). Length of stay was defined
as an outcome, because 90% of patients at our emergency
department undergo angiographic study in 48 hours. In
this setting, reinfarction or refractory angina are infrequent
events at hospitalization. Mean length of stay was 10.5 and
median 3.8 days (range: 0.4 to 124.6), and follow-up mean
was 21.7 and median 23.2 months (range: 0.11 to 31.7),
until September 2007. Long-term outcomes included death
or death and hospital readmission for all causes.
Blood samples were collected at admission to the emer-
gency department. For BNP determination, a specific kit
for the ADVIA Centaur analyzer (Bayer Health Care Diag-
nostics, Tarrytown, NY) was used, with detection limit
of 2 pg/mL and range from 2 to 5000 pg/mL. The intra-
and inter-assay coeﬃcients of variation ranged from 2.1
to 4.7% for concentrations between 29 and 1700 pg/mL.
Echocardiographic data were collected in second day of
admission and ejection fraction was obtained. We calculated
the best point of BNP in receiver operating characteristic
(ROC) curve equal to 300 pg/mL, the highest point of
Youden’s Index [10]. We selected the level of hyperglycemia
above 200mg/dL to separate the highest stratum seen in
the literature [11] for admission nonfasting blood glucose.
Previous use of medication were assessed.
2.3. Statistical Analysis. All data are described as rates and
frequencies or means with standard deviations, as appropri-
ate. Diﬀerences in the distribution of selected characteristics
between patient groups were examined using the chi-square
test and Fisher’s exact test for categorical variables. The anal-
ysis was performed using the Student’s t-test for normally
distributed continuous variables and theMann-Whitney and
Kruskal-Wallis tests for nonparametric variables. Pearson
correlation coeﬃcients were used to study the correlations.
We built an adjusted model in multivariate regression to
analyze the independent variables associated with in-hospital
death or combined in-hospital death and length of stay > 10
days: age, hypertension, smoking, diabetes, blood glucose <
or ≥ 200mg/dL, BNP < or ≥ 300 pg/mL, sex, and serum
creatinine. The ROC curve was used to determine the area
under the curve (AUC) of the C statistic. Cox regression
model was used to evaluate independent prognostic factors
of mortality and hospital readmission for all causes in the
follow-up period. Two-sided P values < 0.05 were considered
statistically significant. All statistical analyses were performed
using SAS software version 9.2 for Windows. To obtain
Youden’s Index, AUC, sensitivity (SENS), specificity (SPEC),
positive predictive value (PPV), negative predictive value
(NPV), and accuracy (ACCU), we used a macro of the SAS
software [12].
3. Results
3.1. Admission Blood Glucose Endpoints. Table 1 presents
clinical and demographic patient characteristics, grouped
by blood glucose < or ≥ 200mg/dL. Univariate analysis
showed a predominance of women (73.7% versus 23.4%; P <
0.001), lower levels of chest pain (68.4% versus 92.2%; P =
0.005), serum hemoglobin (11.8 versus 13.9 g/dL; P < 0.001),
coronary angiographic study (73.7% versus 93.5%; P =
0.011), and higher levels of diabetes (94.7% versus 38.9%;
P < 0.001), heart rate (102.7 versus 77.3 beats/minute; P <
0.001), BNP (660.8 versus 283.7 pg/mL; P < 0.001), white
blood cell count (11,722.2 versus 9,437.3 cells/mm3; P =
0.010), platelet count (294,889.0 versus 221,118.0 cells/mm3;
P < 0.001), serum urea (65.5 versus 49.5mg/dL; P = 0.033),
serum creatinine (1.81 versus 1.20mg/dL; P = 0.016), Killip
presentation ≥ 2 (47.4% versus 13.0%; P < 0.001), length of
stay (22.8 versus 7.4 days; P < 0.001), in-hospital mortality
(26.3% versus 2.6%; P < 0.001), and combined prolonged
length of stay or death (63.2% versus 16.9%; P < 0.001) in
the ≥200mg/dL blood glucose group.
3.2. BNP Endpoints. Table 2 presents clinical and demo-
graphic patient characteristics, but grouped by BNP < or
≥ 300 pg/mL. The BNP ≥ 300 pg/mL group were older
(69.2 versus 62.9 years; P = 0.012) and had lower levels
of chest pain (66.7% versus 98.4%; P < 0.001), systolic
blood pressure (125.6 versus 144.5mmHg; P = 0.005),
diastolic blood pressure (75.2 versus 87.7mmHg; P <
0.001), hemoglobin (12.4 versus 14.1 g/dL; P < 0.001),
ejection fraction (37.9% versus 49.3%; P = 0.001), coronary
angiography study (75.8% versus 96.8%; P = 0.001), and
higher levels of diabetes (69.7% versus 39.7%; P = 0.005),
heart rate (94.9 versus 75.6 beats/minute; P = 0.001), serum
urea (67.5 versus 44.8mg/dL; P < 0.001), serum creatinine
(1.76 versus 1.11mg/dL; P = 0.002), blood glucose (213.9
versus 120.2mg/dL; P < 0.001), Killip presentation ≥ 2
(45.5% versus 6.3%; P < 0.001), medical therapy alone
(51.5% versus 28.6%; P = 0.027), length of stay (16.4 versus
7.4 days; P = 0.022), in-hospital mortality (15.2% versus
3.2%; P = 0.032), and combined prolonged length of stay
or death (48.5% versus 14.3%; P < 0.001). No diﬀerence was
found in two-year mortality or readmission for all causes in
BNP or hyperglycemic subgroups.
3.3. Combination of Laboratory Factors. Inmultivariate logis-
tic analysis of the in-hospital period, the adjusted model
showed only hyperglycemia ≥ 200mg/dL as an independent
predictor of mortality (OR = 13.036, IC 95% 2.296–74.022;
P < 0.001). Hyperglycemia ≥ 200mg/dL (OR = 4.588;
IC 95% 1.348–15.610; P < 0.001) and BNP ≥ 300 pg/mL
(OR = 3.366, IC 95% 1.108–10.223; P = 0.027) were
independent predictors of length of stay longer than 10 days
or death. Table 3 summarizes AUC, sensitivity, specificity,
positive predictive value, negative predictive value, and
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Table 1: Clinical and demographic patient characteristics, grouped by blood glucose ≥ or < 200mg/dL.
All Glucose < 200mg/dL Glucose ≥ 200mg/dL P
Patients, n (%) 96 77 (80.2) 19 (19.8)
Age (years)∗ 65.1 (11.7) 64.9 (12.0) 65.7 (10.7) 0.791
Male, n (%) 64 (66.7) 59 (76.6) 5 (26.3) <0.001
Prior coronary artery disease, n (%) 57 (59.4) 43 (55.8) 14 (73.7) 0.156
Hypertension, n (%) 86 (89.6) 67 (87.0) 19 (100) 0.097
Current smoker, n (%) 16 (16.7) 13 (16.7) 3 (15.8) 0.909
Dyslipidemia, n (%) 65 (67.7) 53 (68.8) 12 (63.2) 0.636
Diabetes mellitus, n (%) 48 (50) 30 (38.9) 18 (94.7) <0.001
Family history of coronary artery disease, n (%) 35 (36.5) 29 (37.7) 6 (31.6) 0.622
Heart rate (beats/minute) 82.6 (27.6) 77.3 (71.9) 102.7 (86.4) <0.001
Systolic blood pressure (mmHg) 137.5 (30.8) 140.2 (29.6) 127.8 (33.7) 0.121
Diastolic blood pressure (mmHg) 83.1 (17.1) 84.8 (16.6) 76.8 (17.6) 0.072
Killip > I, n (%) 19 (19.8) 10 (13.0) 9 (47.4) <0.001
Admission glucose (mg/dL) 152.4 (100.0) 113.1 (31.8) 311.9 (122.8) <0.001
BNP (pg/mL) 358.3 (381.0) 283.7 (339.3) 660.8 (399.4) <0.001
Hemoglobin (g/dL) 13.5 (2.1) 13.9 (1.9) 11.8 (2.2) <0.001
White blood cell count (/mm3) 9879.6 (3418.4) 9437.3 (3181.0) 11722.2 (3838.3) 0.010
Platelet count (/mm3) 235244.7 (82837.8) 221118.0 (73987.4) 294889.0 (93436.3) <0.001
Serum urea (mg/dL) 52.7 (29.4) 49.5 (25.9) 65.5 (38.6) 0.033
Serum creatinine (mg/dL) 1.33 (1.00) 1.20 (0.48) 1.81 (1.98) 0.016
Creatinine kinase-MB (CKMB) peak (ng/mL) 65.1 (111.1) 73.2 (119.5) 32.5 (58.7) 0.154
Troponin I (ng/mL) 25.8 (40.6) 26.5 (41.9) 23.1 (35.6) 0.741
Cholesterol (mg/dL) 175.0 (39.4) 174.7 (39.7) 176.4 (39.3) 0.892
HDL-C (mg/dL) 41.0 (10.9) 40.9 (10.9) 41.5 (11.2) 0.872
LDL-C (mg/dL) 110.6 (32.5) 110.0 (32.9) 113.4 (321.2) 0.732
Triglycerides (mg/dL) 130.4 (76.2) 129.2 (72.4) 136.0 (95.9) 0.772
Ejection fraction (%) 44.7 (15.3) 46.4 (14.3) 39.4 (17.4) 0.083
Angiography, n (%) 86 (89.6) 72 (93.5) 14 (73.7) 0.011
Medical therapy, n (%) 35 (36.5) 26 (33.8) 9 (47.4) 0.270
Percutaneous coronary intervention, n (%) 49 (57.0) 43 (59.7) 6 (42.9) 0.243
Surgery, n (%) 12 (12.5) 8 (10.4) 4 (21.0) 0.208
Length of stay (days) 10.5 (18.6) 7.4 (12.9) 22.8 (30.2) <0.001
Followup (months) 21.7 (9.7) 22.5 (8.7) 18.2 (12.8) 0.084
Mortality, n (%) 17 (17.7) 11 (14.3) 6 (31.6) 0.077
In-hospital, n (%) 7 (7.3) 2 (2.6) 5 (26.3) <0.001
Followup, n (%) 10 (11.2) 9 (12.0) 1 (7.1) 0.597
In-hospital mortality + prolonged length of stay, n (%) 25 (26.0) 13 (16.9) 12 (63.2) <0.001
Follow-up mortality + readmission, n (%) 51 (57.3) 43 (57.3) 8 (57.1) 0.989
accuracy of blood glucose and BNP for in-hospital death
prediction, and Figure 1 shows ROC curve comparison
of only blood glucose and BNP. Although blood glucose
had been slightly better, there was no diﬀerence between
admission glucose and BNP in in-hospital NSTEMI death
prediction. In long-term followup, Cox regression (Figure 2)
failed to show any independent predictors of mortality or
combined hospital readmission for all causes or death. We
analyzed the correlation between blood glucose and BNP, as
shown in Table 4. There is a significant correlation between
glycemia and BNP (Pearson correlation coeﬃcient (PCC) =
0.38; P < 0.001), glycemia and hemoglobin (PCC = 0.41;
P < 0.001), BNP and creatinine (PCC = 0.29; P = 0.004),
and BNP and hemoglobin (PCC = 0.34; P < 0.001).
4. Discussion
4.1. Hyperglycemia and BNP Mortality of ACS. Hyper-
glycemia is a factor long associated with ACS mortality [13],
and its capacity for predicting a worse prognosis in NSTEMI,
in our study, is at least comparable to that of BNP or better
if we consider only death as the outcome. Several studies
accessing BNP and admission glucose separately in ACS
patients showed in-hospital and long-term prognosis around
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Table 2: Clinical and demographic patient characteristics, grouped by BNP ≥ or < 300 pg/mL.
All BNP < 300 pg/mL BNP ≥ 300 pg/mL P
Patients, n (%) 96 63 (65.6) 33 (34.4)
Age (years)∗ 65.1 (11.7) 62.9 (11.1) 69.2 (12.0) 0.012
Male, n (%) 64 (66.7) 46 (73.0) 18 (54.5) 0.068
Prior coronary artery disease, n (%) 57 (59.4) 34 (54.0) 23 (69.7) 0.136
Hypertension, n (%) 86 (89.6) 54 (85.7) 32 (97.0) 0.086
Current smoker, n (%) 16 (16.7) 12 (19.0) 4 (12.1) 0.387
Dyslipidemia, n (%) 65 (67.7) 43 (68.3) 22 (66.7) 0.874
Diabetes mellitus, n (%) 48 (50) 25 (39.7) 23 (69.7) 0.005
Family history of coronary artery disease, n (%) 35 (36.5) 25 (39.7) 10 (30.3) 0.365
Heart rate (beats/minute) 82.6 (27.6) 75.6 (21.8) 94.9 (32.4) 0.001
Systolic blood pressure (mmHg) 137.5 (30.8) 144.5 (29.7) 125.6 (29.3) 0.005
Diastolic blood pressure (mmHg) 83.1 (17.1) 87.7 (16.7) 75.2 (14.9) <0.001
Killip > I, n (%) 19 (19.8) 4 (6.3) 15 (45.5) <0.001
Admission glucose (mg/dL) 152.4 (100.0) 120.2 (46.9) 213.9 (139.6) <0.001
Admission glucose ≥ 200mg/dL, n (%) 19 (19.8) 4 (6.3) 15 (45.5) <0.001
BNP (pg/mL) 358.3 (381.0) 142.9 (87.6) 769.6 (387.5) <0.001
Hemoglobin (g/dL) 13.5 (2.1) 14.1 (1.8) 12.4 (2.2) <0.001
White blood cell count (/mm3) 9879.6 (3418.4) 9459.0 (3166.8) 10681.3 (3775.9) 0.102
Platelet count (/mm3) 235244.7 (82837.8) 232967.0 (71510.4) 239455.0 (101620.0) 0.719
Serum urea (mg/dL) 52.7 (29.4) 44.8 (19.0) 67.5 (38.7) <0.001
Serum creatinine (mg/dL) 1.33 (1.00) 1.11 (0.39) 1.76 (1.55) 0.002
Creatinine kinase-MB (CKMB) peak (ng/mL) 65.1 (111.1) 60.1 (99.9) 74.7 (131.0) 0.542
Troponin I (ng/mL) 25.8 (40.6) 20.0 (32.7) 36.9 (51.2) 0.056
Cholesterol (mg/dL) 175.0 (39.4) 180.0 (37.9) 165.5 (41.1) 0.122
HDL-C (mg/dL) 41.0 (10.9) 40.9 (10.3) 41.3 (12.1) 0.886
LDL-C (mg/dL) 110.6 (32.5) 114.0 (31.3) 103.7 (34.2) 0.190
Triglycerides (mg/dL) 130.4 (76.2) 129.9 (65.3) 131.1 (94.5) 0.947
Ejection fraction (%) 44.7 (15.3) 49.3 (14.6) 37.9 (13.9) 0.001
Angiography, n (%) 86 (89.6) 61 (96.8) 25 (75.8) 0.001
Medical therapy, n (%) 35 (36.5) 18 (28.6) 17 (51.5) 0.027
Percutaneous coronary intervention, n (%) 49 (57.0) 38 (62.3) 11 (44.0) 0.119
Surgery, n (%) 12 (12.5) 7 (11.1) 5 (15.2) 0.570
Length of stay (days) 10.5 (18.6) 7.4 (14.7) 16.4 (23.5) 0.022
Followup (months) 21.7 (9.7) 22.7 (8.3) 19.7 (11.9) 0.143
Mortality, n (%) 17 (17.7) 8 (12.7) 9 (27.3) 0.076
In-hospital, n (%) 7 (7.3) 2 (3.2) 5 (15.2) 0.032
Followup, n (%) 10 (11.2) 6 (9.8) 4 (14.3) 0.537
In-hospital mortality + prolonged length of stay, n (%) 25 (26.0) 9 (14.3) 16 (48.5) <0.001
Follow-up mortality + readmission, n (%) 51 (57.3) 36 (59.0) 15 (53.4) 0.630
the world [14–19]. The decision to use blood glucose or BNP
laboratory results instead of multifactorial models can be
more useful for emergency physicians.
Admission hyperglycemia could be a biochemical marker
for unfavorable ACS prognosis only reflecting inappropri-
ate diabetes control, as another risk factor, and reflect-
ing advanced atherosclerosis. In fact, hyperglycemic ACS
patients usually have a history of diabetes and elevated
HbA1C [20]. On the other hand, hyperglycemia could be
a signal of adrenergic stress response [21] of a severely
ill ACS patient, as observed in other acute illnesses [22].
However, some studies with cardiac magnetic resonance [23,
24] have shown that hyperglycemic or diabetic patients have
greater myocardial infarct size and greater microvascular
obstruction, prothrombotic state, or endothelial dysfunction
[25], or in other words, hyperglycemia could be itself
involved in mechanisms of impaired blood nutrition to the
ischemic wall.
4.2. Marker or Risk Factor? Hyperglycemia could itself
damage coronary endothelia, but there are no convincing
data supporting strategies of intensive insulin therapy to
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Table 3: Comparison of BNP and blood glucose in outcome predictions. Area under the curve, sensitivity, specificity, positive predictive
value, negative predictive value, and accuracy.
Biochemical factor Point AUC∗
Sensitivity
(%)
Specificity
(%)
PPV (%)∗ NPV (%)∗
Accuracy
(%)
P†
In-hospital mortality 0.411
Glucose (mg/dL) 200 0.819 71.4 84.3 26.3 97.4 83.3
BNP (pg/mL) 300 0.748 71.4 68.5 15.2 96.8 68.7
Combined length of stay≥ 10 days or in-hospital mortality 0.339
Glucose (mg/dL) 200 0.697 48.0 90.1 63.2 83.1 79.2
BNP (pg/mL) 300 0.760 64.0 76.1 48.5 85.7 72.9
Combined hospital readmission or mortality 0.343
Glucose (mg/dL) 200 0.524 15.7 84.3 42.9 57.3 55.1
BNP (pg/mL) 300 0.4631 34.2 70.6 46.4 59 55.1
∗
AUC: area under the curve; PPV: positive predictive value; NPV: negative predictive value; †comparison AUC admission blood glucose versus BNP.
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Figure 1: Comparison of glucose versus BNP ROC curve.
control hyperglycemia in critically ill or myocardial infarcted
patients that could reverse the increased mortality, most
probably due to hypoglycemic risk [26], another great
mortality risk factor in the hospital setting. In this context,
both blood glucose and BNP are better as prognostic
markers in ACS patients. For example, elevated BNP can
predict anterior wall ischemic localization at angiography in
NSTEMI [27].
In our study, BNP and blood glucose were better mark-
ers of in-hospital outcomes. Admission hyperglycemia is
associated with long-term risk for ACS mortality [28],
but this association is not homogeneous in diﬀerent ACS
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Figure 2: Adjusted two-year event-free survival, according to BNP
< or ≥ 300 pg/mL.
Table 4: Correlations between blood glucose, BNP, hemoglobin,
and creatinine.
Factor 1 Factor 2 P value
Pearson Correlation
Coeﬃcient
Glycemia BNP <0.001 0.381
Glycemia Creatinine 0.140 0.153
Glycemia Hemoglobin <0.001 0.413
BNP Creatinine 0.004 0.292
BNP Hemoglobin <0.001 −0.348
Hemoglobin Creatinine 0.008 −0.273
presentations [15], unstable angina, NSTEMI, or STEMI.
Besides, mortality up to 1 year can be predicted both by
admission glucose and fasting blood glucose, but the better
predictor of mortality for longer periods is fasting glucose
[29].
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Correlations between BNP, glycemia, hemoglobin, and
creatinine illustrated how measurement of one laboratory
element can in fact assess other components of body home-
ostasis, becoming more diﬃcult to separate a few inde-
pendent mortality risk factors in adjusted complex models.
These factors may be not related in a particular patient, or all
factors could exist in consequence of a common combination
of diseases: obesity, hypertension and diabetes leading to kid-
ney disease, coronary disease, heart failure, anemia, elevated
BNP.
In-hospital stay was defined by clinical criteria. More se-
vere patient were related to in-hospital mortality or required
more time to be discharged from hospital. Hyperglycemia
and BNP are markers of this severity of illness.
4.3. ROC Curve. At a cutoﬀ point of 200mg/dL for blood
glucose and 300 pg/dL for BNP, ROC curve analysis showed
modest values of sensitivity and specificity, but a great
negative predictive value for mortality. Eggers et al. [30]
compared NT-pro BNP, CRP, cystatin C, and creatinine
clearance to predict reinfarction or death in patients with
chest pain and ACS non-STEMI. They found AUC = 0.80
in a composite of abnormal EKG, increased cardiac troponin
I and NT-pro BNP, best NT-pro BNP cutoﬀ point =
550ng/L, sensitivity around 77%, and specificity around
20%, according to the ROC curve. Correia et al. [31] studied
NSTEMI patients and found no improvement in the Grace
Score prediction model of in-hospital events with addition
of admission glucose to the model: AUC increased from 0.81
to 0.82.
The comparison between admission blood glucose and
BNP ROC curves showed no statistical diﬀerence, but we
believe that blood glucose could be more useful in risk strat-
ification of ACS patients mainly in undeveloped countries,
where cost limits the adoption of new technologies.
4.4. Study Limitations. We determined admission laboratory
results as variables to be studied to evaluate risks beyond
clinical scores like Grace or TIMI risk.We did not compare or
add BNP and blood glucose to the models of risk prediction,
but we simplified NSTEMI assessment by using unadjusted
results to predict mortality or higher length of stay.
Some aspects of the study population like prevalence of
previous coronary artery disease in up to three-quarters of
patients could influence initial BNP or blood glucose and the
in-hospital prognosis.
5. Conclusion
This study suggests that hyperglycemia is an independent
risk factor of in-hospital mortality in NSTEMI and has a
good ROC curve level. Although poor in-hospital predictors
of unfavorable events, both hyperglycemia and BNP were
independent risk factors for death or length of stay > 10 days.
There was no relation between hyperglycemia or BNP with
long-term events in our NSTEMI patients.
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